High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
about
Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic reviewOncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesAn Integrative Approach to Precision Cancer Medicine Using Patient-Derived XenograftsRB1: a prototype tumor suppressor and an enigmaApproaches to modernize the combination drug development paradigmImproving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assaysGenetically engineered mouse models in oncology research and cancer medicinePatient-derived tumour xenografts for breast cancer drug discoveryCetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signatureA Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In VivoMetformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived XenograftsA Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsEstablishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients.Gastric Cancer in the Era of Precision Medicine.Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast CancerEarly Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model.Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models.Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data.Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinomaOverview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes.Modeling pancreatic cancer with organoidsBRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived XenograftsImproving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials.Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts.Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma.The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.Patient-Derived Xenograft Models of Non-Small Cell Lung Cancer and Their Potential Utility in Personalized Medicine.Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.Targeting and Regulating of an Oncogene via Nanovector Delivery of MicroRNA using Patient-Derived Xenografts.Human pancreatic cancer xenografts recapitulate key aspects of cancer cachexia.Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies.Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance.Advances in computational approaches in identifying synergistic drug combinations.Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest.TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication.Looking beyond the cancer cell for effective drug combinations.Patient-derived xenografts as tools in pharmaceutical development.Combine and conquer: challenges for targeted therapy combinations in early phase trials.
P2860
Q26741651-DBED6C35-1146-450D-8650-B1FFB4392B59Q26768158-82E385D2-5D07-4305-A74D-9F0890EDF4D5Q26772895-51BFEA53-E8F3-49A7-970F-5BF18903736DQ26866393-B9BCE208-7447-4ADC-83A0-707F26C95C83Q28072074-CBF5E0D5-4FCA-4355-8AA5-33CE5513D746Q28077848-3F1ACAEA-A116-446A-A79F-3386039ABEAEQ28079323-2FBB1CFB-763A-4CFD-B6F5-30DF6C0759DBQ28080046-4D4B955A-73A5-4379-A51D-E88AFE66299CQ28468648-CF187275-98BD-4302-9725-324213C139DDQ28552262-93F03F59-A07A-499C-9B17-CEE144506D7CQ28552408-8E4CB188-A9B9-4917-8419-E71964FA42D5Q28598343-D6A454AE-102F-46E5-BEF5-B562573F06B1Q33582635-87392631-AC2D-4109-BD46-715FE376D028Q33600457-D2F3DFA6-4D8A-455E-9458-DA12DE9948ADQ33614238-587F4E24-308B-42DA-949C-F16D8E43E7FBQ33660573-356C0A36-22A5-4A1F-B8DC-10EE813F95BDQ33767369-AAD6F893-C4C0-4DA1-A9B0-AE8BD3638741Q33779673-36FF2744-D4CB-4916-A5DA-435136DE2A57Q36309864-AC156151-D79F-42E7-B184-5734F6DB74E8Q36646313-4C7790E4-E168-4252-AD8D-85D5943F1E98Q36784065-F0A92EDD-7B36-4DB5-99FC-718FD6EE4AC7Q36842030-FF645A40-C83F-4403-ACD5-308B5C955767Q37056708-9822967A-9666-4A70-9B6F-2AC01B5FC606Q37059799-2FE6D28C-819C-4D39-97CE-E3B109D36C8AQ37269137-45124010-0AE6-4A36-AA56-1DBA6496ECB6Q37272622-0052DA29-C132-43A4-AAC3-7DF17A340C98Q37526352-EDC05EAB-9A4E-42D2-AC26-B552041059B1Q37592628-C4FC17F5-C6C2-4CCE-B94F-60147DD96956Q37642614-097C2C0C-0282-4121-8C0B-280C359BC8A4Q37668563-423D9D51-BA0E-46A1-A4FF-B73FCE263A5CQ37702064-8AAFCD1B-D9E2-4086-8193-2DE9D78844F1Q38605171-C9FEBF24-9B64-4BAB-A7CF-834DB732C97CQ38628538-A838CB09-D677-45E2-AA8F-3AAC415353A1Q38687343-036FD5DF-CB45-411D-AE08-7404FCA0FD1EQ38707876-521B349A-F9EA-4F7A-91A3-9C7B1A3F1CACQ38723383-D70A61F4-64DD-442C-96D7-6C152A1B34FCQ38726203-00500598-FFA1-46CE-8C7B-642879C480E0Q38728970-7DCE2D3B-C04A-4AEA-9F11-E491A7C88186Q38732336-708396E8-6790-4DA3-BF4E-BAF922F79153Q38734451-10A5A880-0D09-41FE-9207-4D40E5C369DC
P2860
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
High-throughput screening usin ...... clinical trial drug response.
@en
type
label
High-throughput screening usin ...... clinical trial drug response.
@en
prefLabel
High-throughput screening usin ...... clinical trial drug response.
@en
P2093
P2860
P921
P356
P1433
P1476
High-throughput screening usin ...... t clinical trial drug response
@en
P2093
Angad P Singh
Anupama Reddy
Audrey Kauffmann
Chao Zhang
Christian Schnell
Claudia Röelli
Colleen Kowal
Daniel Wyss
David A Ruddy
P2860
P2888
P304
P356
10.1038/NM.3954
P407
P577
2015-10-19T00:00:00Z